More than 1.9 billion people are overweight globally (body mass index, BMI >25), 650 million of which have obesity (BMI >30).[i] Projections expect these numbers to almost double by 2025, further aggravating the considerable burden for patients and the healthcare systems.
Obesity is far more than just excess weight. It is a systemic multi-organ disease with many clinical manifestations bridging the broad spectrum from type 2 diabetes to cardiovascular to neurological disorders.
A lack of effective treatment options and limited access to existing treatments leaves more than 98% of patients with obesity untreated. One last resort treatment reserved for patients with a body mass index above 40 is Roux-Y-Gastric Bypass surgery (RYGB), a highly invasive procedure that aims to reduce the storage volume for food by surgically bypassing the stomach. RYGB patients benefit from 28% of weight loss on average over time, which is permanent in most cases, but also suffer from a variety of massive long-term side effects.